Identification of microRNAs as potential biomarkers for lung adenocarcinoma using integrating genomics analysis
Metrics: PDF 1543 views | HTML 2873 views | ?
Zhuo Peng1, Longfei Pan1, Zequn Niu1, Wei Li2, Xiaoyan Dang1, Lin Wan1, Rui Zhang1 and Shuanying Yang2
1Department of Emergency Medicine, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
2Department of Respiratory Medicine, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Shuanying Yang, email: [email protected]
Keywords: microRNAs, lung adenocarcinoma, robust rank aggregation
Received: March 20, 2017 Accepted: June 05, 2017 Published: July 18, 2017
Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer, but novel biomarkers for early diagnosis are lacking. Extensive effort has been exerted to identify miRNA biomarkers in LUAD. Unfortunately, high inter-lab variability and small sample sizes have produced inconsistent conclusions in this field. To resolve the above-mentioned limitations, we performed a comprehensive analysis based on LUAD miRNome profiling studies using the robust rank aggregation (RRA) method. Moreover, miRNA-gene interaction network, pathway enrichment analysis and Kaplan-Meier survival curves were used to investigate the clinical values and biological functions of the identified miRNAs. A total of six common differentially expressed miRNAs (DEMs) were identified in LUAD. An independent cohort further confirmed that four miRNAs (miR-21-5p, miR-210-3p, miR-182-5p and miR-183-5p) were up-regulated and two miRNAs (miR-126-3p and miR-218-5p) were down-regulated in LUAD tissues. Pathway enrichment analysis also suggested that the above-listed six DEMs may affect LUAD progression via the estrogen signaling pathway. Survival analysis based on the TCGA dataset revealed the potential prognostic values of six DEMs in patients with LUAD (P-value<0.01). In conclusion, we identified a panel of six miRNAs from LUAD using miRNome profiling studies. Our results provide evidence for the use of these six DEMs as novel diagnostic and prognostic biomarkers for LUAD patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.